Breo Ellipta is an anti-asthma drug owned by Glaxo Grp Ltd. This medication contains an active ingredient Fluticasone Furoate and Vilanterol Trifenatate. Breo Ellipta had its first market authorization on 10 May, 2013 and currently holds a total of 18 patents, out of which 2 have expired.
The generic version of Breo Ellipta may potentially be available after the expiration of its last patent on 11 April, 2031. This is conceivable because post-expiration, there could be room for other manufacturers to produce a generic version of the drug, bringing the drug to more patients at a more affordable cost. The Breo Ellipta generic release date depends on the expiry of the patents.
Breo Ellipta is primarily used for the once-daily inhaled treatment for asthma in adults aged 18 years and older. It can also be used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It may also help reduce exacerbations of COPD in patients with a history of exacerbations.
Breo Ellipta holds several patents with many diverse aspects including medicament dispencers and pharmaceutical formulations. The final patent is expected to expire on 11 April, 2031, after which the possibility for a Breo Ellipta generic could emerge. Below is the details of the patent: